mCSPC

Outcomes Associated With Bone-Modifying Agents in Patients With High-Risk mCSPC
There is a lack of research on the effects of bone-modifying agents (BMAs) in patients with metastatic castration-sensitive prostate cancer (mCSPC) who underwent treatment with abiraterone acetate plus prednisone (AAP). A study from Wataru Fukuokaya, MD, and colleagues, published in JAMA Network Open, sought to determine the outcomes associated with BMAs in patients with mCSPC who received AAP. ...
Advertisement
Advertisement

Prostate Cancer Knowledge Hubs

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Latest News